b cell leukemia


Summary: A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.

Top Publications

  1. Ottensmeier C. The classification of lymphomas and leukemias. Chem Biol Interact. 2001;135-136:653-64 pubmed
    ..It is also clear that no single marker, be it morphology, genetic analysis or immunophenotyping can be used as the 'gold standard' for diagnosis but that a combination of techniques is needed...
  2. Lee M, Kim J, Koh W. Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia. J Cell Biochem. 2004;93:629-38 pubmed
    ..a potent and selective inhibitor of the Src-family tyrosine kinase, can lead to cell death in murine B cell leukemia, 70Z/3...
  3. Martinez Lostao L, Briones J, Martinez Gallo M, Forne I, Sierra J, Rodriguez Sanchez J, et al. Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect. Leuk Lymphoma. 2004;45:2307-14 pubmed
    ..In conclusion, apoptosis induced by fludarabine in CD19+/CD5+B-CLL cells was due to a direct effect on these cells and not due to its effect in the NLCs...
  4. Luciano F, Ricci J, Herrant M, Bertolotto C, Mari B, Cousin J, et al. T and B leukemic cell lines exhibit different requirements for cell death: correlation between caspase activation, DFF40/DFF45 expression, DNA fragmentation and apoptosis in T cell lines but not in Burkitt's lymphoma. Leukemia. 2002;16:700-7 pubmed
    ..66) to apoptosis. Thus it seems that resistance of Burkitt's lymphoma to apoptosis is not governed by a general mechanism, but is rather multifactorial and differs from one cell line to another...
  5. Wang C, Amato D, Rabah R, Zheng J, Fernandes B. Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5(-) CLL. Leuk Res. 2002;26:1125-9 pubmed
    ..All the patients with MLUS were found to have a mild and non-progressing lymphocytosis with CD5(-) phenotype. These features may be used to differentiate them from CLL. ..
  6. Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka I. CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia. 2005;19:301-4 pubmed
  7. Rubio M, Saito T, Kattleman K, Zhao G, Buchli J, Sykes M. Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-. J Immunol. 2005;175:665-76 pubmed
    ..The pathways of donor marrow and tumor rejection lead to the development of tumor-specific cell-mediated cytotoxic responses that are not due to bystander killing by alloreactive T cells...
  8. Uckun F, Dibirdik I, Qazi S, Yiv S. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells. Arzneimittelforschung. 2010;60:210-7 pubmed publisher
    ..0001). These experimental results demonstrate that the nanotechnology-enabled delivery of WHI-P131 shows therapeutic potential against leukemias with constitutive activation of the JAK3-STAT3/STAT5 molecular target. ..
  9. Luksiene Z, Eggen I, Moan J, Nesland J, Peng Q. Evaluation of protoporphyrin IX production, phototoxicity and cell death pathway induced by hexylester of 5-aminolevulinic acid in Reh and HPB-ALL cells. Cancer Lett. 2001;169:33-9 pubmed
    ..Reh cells appear to be more sensitive than HPB-ALL cells to ALA hexylester-mediated phototoxicity. Apoptosis was the major cell death pathway of Reh cells, while necrosis played a major role in the case of HPB-ALL cells. ..

More Information

Publications116 found, 100 shown here

  1. Menter T, Trivedi P, Ahmad R, Flora R, Dirnhofer S, Tzankov A, et al. Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas. Am J Clin Pathol. 2017;147:292-300 pubmed publisher
    ..96, and specificity was 0.93. In this study, we could demonstrate the diagnostic utility of LEF1. LEF1 is a sensitive and specific marker for CLL and is helpful in the diagnosis of diagnostically challenging small B-cell lymphomas. ..
  2. Rawstron A. Prevalence and characteristics of monoclonal B-cell lymphocytosis (MBL) in healthy individuals and the relationship with clinical disease. J Biol Regul Homeost Agents. 2004;18:155-60 pubmed
    ..These cells provide a tool for studying the events responsible for disease initiation...
  3. Jo S, Schatz J, Acquaviva J, Singh H, Ren R. Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood. 2010;116:2759-67 pubmed publisher
    ..Combined losses of IRF-4 and IRF-8 therefore can cooperate in the development of both myeloid and lymphoid tumors. ..
  4. Dorfman D, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms. Am J Clin Pathol. 2010;134:726-33 pubmed publisher
    ..Furthermore, since an anti-CD200 immunotherapeutic agent is in clinical trials, a number of B cell-derived neoplasms in addition to CLL/SLL may be suitable therapeutic targets. ..
  5. Barth S. Technology evaluation: BL22, NCI. Curr Opin Mol Ther. 2002;4:72-5 pubmed
    ..It is composed of the disulfide-stabilized Fv portion of the anti-CD22 antibody RFB4 genetically fused to a truncated form of Pseudomonas exotoxin A. It has entered phase I trials for the treatment of B-cell lymphoma. ..
  6. Weiss L, Reich S, Mandelboim O, Slavin S. Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy. Bone Marrow Transplant. 2004;33:1137-41 pubmed
    ..BCL1 cells express ligands for NKp46 on the cell surface membrane and they are sensitive to allogeneic but not syngeneic IL-2 activated natural killer cells. ..
  7. Yeol S, Won Y, Kim Y, Lee J, Choi Y, Park D. Decreased Bcl-6 and increased Blimp-1 in the peritoneal cavity of patients with endometriosis. Clin Exp Obstet Gynecol. 2015;42:156-60 pubmed
    ..and tumor necrosis factor (TNF)-α, cytokines associated with peritoneal inflammatory reactions, and of B cell leukemia lymphoma (Bcl)-6 and B lymphocyte inducer of maturation program (Blimp)-1, transcriptional factors associated ..
  8. Condomines M, Arnason J, Benjamin R, Gunset G, Plotkin J, Sadelain M. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS ONE. 2015;10:e0130518 pubmed publisher
    ..In an aggressive pre-B cell leukemia model, mice treated with 19-28z+ T cells had 10-fold reduced tumor progression compared to those treated with ..
  9. Greenwald R, Tumang J, Sinha A, Currier N, Cardiff R, Rothstein T, et al. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood. 2004;103:1475-84 pubmed
    ..This report is the first to describe a transgenic mouse model for constitutive expression of a protein with more than one bromodomain. ..
  10. Tobin G. The immunoglobulin genes and chronic lymphocytic leukemia (CLL). Ups J Med Sci. 2005;110:97-113 pubmed
    ..In summary, we could define new prognostic subgroups in CLL using Ig gene rearrangement analysis. This also allowed us to gain insights in the biology and potential role of antigen involvement in the pathogenesis of CLL. ..
  11. Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica. 2009;94:870-4 pubmed publisher
    ..01%) was 86% (n=134). Thus, this standardized protocol is highly reproducible between laboratories, sensitive, applicable, and shows good concordance with molecular-based analysis...
  12. Smeenk L, Fischer M, Jurado S, Jaritz M, Azaryan A, Werner B, et al. Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia. EMBO J. 2017;36:718-735 pubmed publisher
    ..Together with similar observations made in human PAX5-ETV6+ B-ALLs, these data identified PAX5-ETV6 as a potent oncoprotein that drives B-cell leukemia development. ..
  13. Jin A, Lei C, Tian J, Sun J, Ji H. Dietary docosahexaenoic acid decreased lipid accumulation via inducing adipocytes apoptosis of grass carp, Ctenopharygodon idella. Fish Physiol Biochem. 2018;44:197-207 pubmed publisher
    ..05). However, the ratio of the expression levels of B cell leukemia 2 (Bcl-2) and Bcl-2-associated X protein (Bax) was significantly lower in the DHA-fed group than in the ..
  14. Inoue A, Seidel M, Wu W, Kamizono S, Ferrando A, Bronson R, et al. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell. 2002;2:279-88 pubmed
    ..These results implicate Slug in a novel survival pathway that protects hematopoietic progenitors from apoptosis after DNA damage. ..
  15. Griffin T, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52:177-81 pubmed publisher
    ..The combination of rituximab and ICE chemotherapy was associated with an encouraging objective response (OR) rate and an acceptable toxicity profile. ..
  16. Hau A, Grebbin B, Agoston Z, Anders Maurer M, Müller T, Groß A, et al. MEIS homeodomain proteins facilitate PARP1/ARTD1-mediated eviction of histone H1. J Cell Biol. 2017;216:2715-2729 pubmed publisher
    ..These results for the first time link MEIS proteins to PARP-regulated chromatin dynamics and provide a mechanistic basis to explain the profound cellular changes elicited by these proteins. ..
  17. Mourad Y, Taher A, Chehal A, Shamseddine A. Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol. 2004;83:319-21 pubmed
    ..She remains in complete remission 8 months following the discontinuation of treatment. This is the second reported case of successful treatment of B-cell PLL with rituximab. ..
  18. Thorselius M, Walsh S, Thunberg U, Hagberg H, Sundstrom C, Rosenquist R. Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. Leuk Res. 2005;29:153-8 pubmed
    ..Furthermore, restricted VH3-30 usage indicates that antigen selection could be a promoting factor in HCL development. ..
  19. Uckun F, Qazi S, Ma H, Tuel Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci U S A. 2010;107:2902-7 pubmed publisher
    ..Notably, inhibition of SYK with a small molecule drug candidate prevents OS-induced activation of STAT3 and overcomes the resistance of human B-lineage leukemia/lymphoma cells to OS-induced apoptosis. ..
  20. Kalinich J, Ramakrishnan R, McClain D, Ramakrishnan N. 4-Hydroxynonenal, an end-product of lipid peroxidation, induces apoptosis in human leukemic T- and B-cell lines. Free Radic Res. 2000;33:349-58 pubmed
    ..These results suggest that peroxidative damage to cellular membranes resulting in the production of HNE may be a trigger for the induction of apoptosis in immune system cells. ..
  21. Yasui H, Hideshima T, Anderson K. Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47:2445-6 pubmed
  22. Groom J, Mackay F. B cells flying solo. Immunol Cell Biol. 2008;86:40-6 pubmed publisher
    ..In conclusion, dysregulated innate activation of B cells alone can drive disease independently of T cells, and as such this aspect represents a new pathogenic mechanism in autoimmunity. ..
  23. Fabbri A, Gozzetti A, Marotta G, Monti L, Menci E, Lenoci M, et al. An unusual presentation of chronic B-cell lymphocytic leukaemia. Br J Haematol. 2004;124:129 pubmed
  24. Feng Y, Li L, Zhang X, Zhang Y, Liang Y, Lv J, et al. Hematopoietic pre-B cell leukemia transcription factor interacting protein is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, migration, and invasion. Cancer Sci. 2015;106:1313-22 pubmed publisher
    Hematopoietic pre-B cell leukemia transcription factor interacting protein (HPIP) has been shown to play an important role in the development and progression of some cancers. However, the role of HPIP in gastric cancer (GC) is unclear...
  25. Wang S, Chai D, Chen C, Wang Z, Wang L. HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway. Biomed Pharmacother. 2015;75:33-9 pubmed publisher
    Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein (HPIP), a co-repressor for the transcription factor PBX, is a nucleo-cytoplasmic shuttling protein...
  26. Letai A, Sorcinelli M, Beard C, Korsmeyer S. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 2004;6:241-9 pubmed
    ..This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s). ..
  27. Kim M, Yoon H, Lim G, Kim S, Lee H, Suh J, et al. ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review. Cancer Genet Cytogenet. 2010;196:184-8 pubmed publisher
    ..Further studies are needed to evaluate the extent of the submicroscopic defects in chromosome 9 including ABL1 gene deletion, as well as treatment response and prognosis in long-term follow-up of such patients. ..
  28. Oelsner S, Friede M, Zhang C, Wagner J, Badura S, Bader P, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19:235-249 pubmed publisher
    ..Our data demonstrate that it is feasible to generate CAR-engineered NK-92 cells with potent and selective antitumor activity. These cells may become clinically useful as a continuously expandable off-the-shelf cell therapeutic agent. ..
  29. Stratowa C, Loffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, et al. CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer. 2001;91:474-80 pubmed
    ..This report demonstrates the feasibility of a systematic integration of large-scale gene expression profiles with clinical data as a general approach for dissecting human diseases. ..
  30. Bolan C, Childs R, Procter J, Barrett A, Leitman S. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol. 2001;112:787-95 pubmed
    ..Meticulous clinical monitoring and early, vigorous donor-compatible red cell transfusions should be practiced in all instances. ..
  31. Wang Y, Liu Y, Hu C, Ni X, Huang X. Tumor necrosis factor ?-induced protein 8-like 1 promotes apoptosis by regulating B-cell leukemia/lymphoma-2 family proteins in RAW264.7 cells. Oncol Lett. 2016;12:3506-3512 pubmed
    ..7 cells by upregulating the pro-apoptotic members of the Bcl-2 family of proteins, and that the MAPKs signaling pathway was not involved in the pro-apoptotic effect of TIPE1. ..
  32. Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods A, et al. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia. Int J Mol Sci. 2017;18: pubmed publisher
  33. Pangalis G, Dimopoulou M, Angelopoulou M, Tsekouras C, Vassilakopoulos T, Vaiopoulos G, et al. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol. 2001;18:99-107 pubmed
    ..More clinical trials in a larger number of patients are necessary to determine the exact role and indications of Campath-1H in lymphoproliferative disorders. ..
  34. Malbora B, Avci Z, Alioglu B, Tutar N, Ozbek N. A case with mature B-cell acute lymphoblastic leukemia and pancreatic involvement at the time of diagnosis. J Pediatr Hematol Oncol. 2008;30:87-9 pubmed publisher
    ..After 2 cycles of chemotherapy, the lesions in his pancreas, liver, and kidney disappeared, and his pancreatitis resolved as well. At 11 months' follow-up, after completion of therapy, the patient continues to be in remission. ..
  35. Thomas Tikhonenko A, Cozma D. PAX5 and B-cell neoplasms: transformation through presentation. Future Oncol. 2008;4:5-9 pubmed publisher
  36. Li Q, Lai Z, Yan Z, Peng J, Jin Y, Wei L, et al. Hedyotis diffusa Willd inhibits proliferation and induces apoptosis of 5?FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway. Mol Med Rep. 2017;: pubmed publisher
    ..The mRNA and protein expression levels of B cell leukemia/lymphoma (Bcl?2), Bcl?2 associated X (Bax), cyclin dependent kinase 4 (CDK4), cyclin D1 and p21 were ..
  37. Lepe Zúñiga J, Jerónimo López F, Hernández Orantes J. [Cytopathologic features of childhood acute leukemia at the Hospital de Especialidades Pediátricas, Chiapas, Mexico]. Bol Med Hosp Infant Mex. 2017;74:122-133 pubmed publisher
    ..3%; myeloid, 16%; T cell, 3.7% and NK 1.2%. In B cell leukemia, genetic alterations were present in 40...
  38. Beliveau R, Gingras D. Green tea: prevention and treatment of cancer by nutraceuticals. Lancet. 2004;364:1021-2 pubmed
  39. Huh Y, Abruzzo L, Rassidakis G, Parry Jones N, Schlette E, Brito Bapabulle V, et al. The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. Br J Haematol. 2007;136:220-8 pubmed
    ..However, these neoplasms also differ from CLL cytologically and in their immunophenotype. ..
  40. Chen Y, Zhao R, Zhao Q, Shao Y, Zhang S. Knockdown of HPIP Inhibits the Proliferation and Invasion of Head-and-Neck Squamous Cell Carcinoma Cells by Regulating PI3K/Akt Signaling Pathway. Oncol Res. 2016;24:153-60 pubmed publisher
    ..Therefore, HPIP may be a novel potential therapeutic target for the treatment of HNSCC. ..
  41. Harig S, Witzens M, Krackhardt A, Trojan A, Barrett P, Broderick R, et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood. 2001;98:2999-3005 pubmed
  42. Polyak M, Ayer L, Szczepek A, Deans J. A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 2003;17:1384-9 pubmed
    ..FMC7 mAb binding thus appears to be a sensitive indicator of the level of plasma membrane cholesterol and reveals a conformational state of CD20 that is regulated by cholesterol. ..
  43. Nygren M, Døsen Dahl G, Stubberud H, Walchli S, Munthe E, Rian E. beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells. Exp Hematol. 2009;37:225-33 pubmed publisher
    ..Instead, beta-catenin is involved in N-cadherin-dependent adherence junctions, suggesting for the first time that leukemia-stroma interactions may be mediated via an N-cadherin-dependent mechanism. ..
  44. Zielinski B, Hergenhahn M. 2-Chloroacetaldehyde induces epsilondA DNA adducts in DNA of Raji cells as demonstrated by an improved HPLC-fluorimetry method. Fresenius J Anal Chem. 2001;370:97-100 pubmed
    ..Our method has a detection limit of 5 fmol which is one two-hundredth that of the original method. By use of this method initial evidence was found that cigarette smoke can also induce etheno dA adducts in Raji cell DNA. ..
  45. Kuriakose P, Perveen N, Maeda K, Wiktor A, Van Dyke D. Translocation (8;14)(q24;q32) as the sole cytogenetic abnormality in B-cell prolymphocytic leukemia. Cancer Genet Cytogenet. 2004;150:156-8 pubmed
  46. Nikolova M, Guenova M, Taskov H, Marie Cardine A, Boumsell L, Bensussan A. SC3 monoclonal antibody defines a novel specific human B-cell surface antigen differentially expressed on B-cell leukaemias and lymphomas and involved in the proliferation of normal and malignant B lymphocytes. Cell Immunol. 2005;236:92-100 pubmed
    ..Although its expression in B-cell malignancies was not limited to a single differentiation stage, it might confer specific functional characteristics to the positive malignant cells. ..
  47. Lim J, Kim H, Kim M, Kim T, Kim E, Kim Y, et al. Cinacalcet-mediated activation of the CaMKKβ-LKB1-AMPK pathway attenuates diabetic nephropathy in db/db mice by modulation of apoptosis and autophagy. Cell Death Dis. 2018;9:270 pubmed publisher
    ..the phosphorylation of endothelial nitric oxide synthase (eNOS) and increases in superoxide dismutases and B cell leukemia/lymphoma 2/BCL-2-associated X protein expression...
  48. Byrd J, Peterson B, Morrison V, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14 pubmed
    ..Phase 3 studies using this combination approach for patients with CLL are warranted. ..
  49. Weinberg O, Arber D. Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia. 2010;24:1844-51 pubmed publisher
    ..Further studies are needed to confirm the significance of MPAL as currently defined, to determine a standardized treatment approach and to better understand the biological and clinical aspects of this disease. ..
  50. Morisot S, Wayne A, Bohana Kashtan O, Kaplan I, Gocke C, Hildreth R, et al. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia. 2010;24:1859-66 pubmed publisher
    ..This very high frequency of LSCs suggests that a hierarchical LSC model is not valuable for poor-outcome ALL...
  51. Tsukada N, Aoki S, Maruyama S, Kishi K, Takahashi M, Aizawa Y. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J Exp Clin Cancer Res. 1997;16:171-6 pubmed
    ..Constitutive expression of CD80 and/or CD86 was frequently observed on B cell leukemia/lymphoma cells, while it is rare on myeloid leukemia cells...
  52. Rodriguez C, Legha J, Estey E, Keating M, Gandhi V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells. Clin Cancer Res. 1997;3:2107-13 pubmed
    ..Extension of these studies to ex vivo incubations confirmed our in vitro findings. These strategies will be used in the design of clinical protocols to increase ara-GTP accumulation in leukemia cells during therapy...
  53. Brisco M, Sykes P, Hughes E, Neoh S, Snell L, Dolman G, et al. Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia. Leukemia. 2001;15:385-90 pubmed
    ..PCR-based methods for measurement of MRD levels should incorporate a correction for variation in DNA amplifiability...
  54. Hentges K, Weiser K, Schountz T, Woodward L, Morse H, Justice M. Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B-cell leukemia. Oncogene. 2005;24:1220-30 pubmed
    ..Further, these data imply that Evi3 misexpression initiates tumorigenesis by perturbing B-cell development via an interaction with EBF...
  55. Jumaa H, Hendriks R, Reth M. B cell signaling and tumorigenesis. Annu Rev Immunol. 2005;23:415-45 pubmed
    ..We point out the concepts of auto-inhibition and subcellular localization as crucial aspects in the regulation of B cell signaling...
  56. Kalled S. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol. 2006;18:290-6 pubmed
    ..These include germinal center maintenance, isotype switching, and regulation of specific B cell surface markers. More importantly, a role for BAFF in B cell biology has been validated in vivo in humans...
  57. Spaapen R, Lokhorst H, van den Oudenalder K, Otterud B, Dolstra H, Leppert M, et al. Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J Exp Med. 2008;205:2863-72 pubmed publisher
    ..The currently available immunotherapy strategies enable the exploitation of these therapeutic effects within and beyond allo-SCT settings...
  58. Brohee D, Cauchie P, Delval L, Govaerts D, Neve P, Piro P. Frequent discordance of the light-chain isotypes expressed by serum monoclonal components and leukaemic B-cells. Clin Lab Haematol. 2002;24:151-4 pubmed
    ..It could be due to the emergence of subclones with the same primal VDJ gene rearrangement or, alternatively, to the development of new B-cell clones escaping immune surveillance from deregulated T-cells...
  59. Weiss L, Abdul Hai A, Shufaro Y, Reich S, Slavin S. Linomide administration following bone marrow transplantation in mice. Cancer Immunol Immunother. 2002;51:596-602 pubmed
    ..Alternatively, linomide might affect the homing of self-reactive lymphocytes to specific target organs in autoimmune disorders, although the homing process may not be relevant to the control of leukemia by alloreactive lymphocytes...
  60. Nakagawa R, Soh J, Michie A. Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo. Cancer Res. 2006;66:527-34 pubmed
    ..Our findings uncover novel avenues not only for the study of the induction of leukemic B cells but also for the development of therapeutic drugs to combat PKC alpha-regulated transformation events...
  61. Muszyńska Rosłan K, Krawczuk Rybak M, Protas P, Hołownia A. Level of tau protein in children treated for acute lymphoblastic leukemia. Pediatr Neurol. 2006;34:367-71 pubmed
    ..This finding requires further studies, also in reference to other central nervous system proteins, and confirms the necessity of long-term follow-up of leukemia patients...
  62. Harrison C, Haas O, Harbott J, Biondi A, Stanulla M, Trka J, et al. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster study group. Br J Haematol. 2010;151:132-42 pubmed publisher
    ..However, cytogenetics, particularly fluorescence in situ hybridization may provide reliable alternative detection methods dependent upon the preferred technical approach within each protocol...
  63. Neglia J, Linet M, Shu X, Severson R, Potter J, Mertens A, et al. Patterns of infection and day care utilization and risk of childhood acute lymphoblastic leukaemia. Br J Cancer. 2000;82:234-40 pubmed
    ..026). No effect of sibship size or birth interval was seen. With one exception (ear infections), these data do not support the hypothesis that a decrease in the occurrence of common childhood infection increases risk of ALL...
  64. Kimby E, Brandt L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncol. 2001;40:224-30 pubmed
    ..In the future an individual risk-adapted therapy will be required. The clinical heterogeneity of the disease has pointed to the necessity of new predictors for prognosis evaluated in prospective trials...
  65. Krynetski E, Krynetskaia N, Bianchi M, Evans W. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucle. Cancer Res. 2003;63:100-6 pubmed
  66. Airoldi I, Raffaghello L, Cocco C, Guglielmino R, Roncella S, Fedeli F, et al. Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes. Clin Cancer Res. 2004;10:144-54 pubmed
    ..Our purpose was to investigate this issue in human naive, germinal center (GC) and memory B cells, and in their neoplastic counterparts...
  67. Jelinek D, Darce J. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoimmun. 2005;8:266-88 pubmed
    ..In this article, we will review the spectrum of human B lineage malignancies and discuss current evidence supporting a role for BLyS and APRIL in fueling the growth and survival of specific B cell malignancies...
  68. Prabhu S, Gottlieb D, Varikatt W, St Heaps L, Diaz S, Smith A. Adult B-cell acute lymphoblastic leukemia with two unrelated abnormal cytogenetic clones. Cancer Genet Cytogenet. 2010;201:24-7 pubmed publisher
    ..The presence of two unrelated clones suggestive of concomitant malignancies, possibly B-ALL with an underlying MDS, may have arisen by different mechanisms...
  69. Buttmann M, Marziniak M, Toyka K, Sommer C, Altland K. "Sporadic" familial amyloidotic polyneuropathy in a German patient with B cell lymphocytic leukaemia. J Neurol Neurosurg Psychiatry. 2002;73:86-7 pubmed
  70. Voso M, Pantel G, Rutella S, Weis M, D Alo F, Urbano R, et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica. 2002;87:918-25 pubmed
    ..It was the objective of this study to define the contribution of the different mechanisms of action of rituximab on primary normal and malignant B-cells...
  71. Belov L, Huang P, Chrisp J, Mulligan S, Christopherson R. Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. J Immunol Methods. 2005;305:10-9 pubmed
  72. O Brien S, Kantarjian H, Thomas D, Giles F, Freireich E, Cortes J, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165-70 pubmed
  73. Kneitz C, Goller M, Tony H, Simon A, Stibbe C, König T, et al. The CD23b promoter is a target for NF-AT transcription factors in B-CLL cells. Biochim Biophys Acta. 2002;1588:41-7 pubmed
  74. Jahrsdorfer B, Blackwell S, Wooldridge J, Taylor C, Weiner G. Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia. Oligonucleotides. 2005;15:51-9 pubmed
    ..In conclusion, systemic short-term application of CpG ODN appears to be sufficient to induce phenotypic changes, but higher doses of CpG ODN than previously thought may be necessary because of inhibition of their uptake by serum...
  75. Gainers M, Rofagha R, English J. Leukemia cutis of the nose. Cutis. 2007;80:208-10 pubmed
    ..In patients with a history of leukemia, histopathologic examination of refractory conditions is essential and should be performed early in the treatment strategy...
  76. Harb J, Chyla B, Huettner C. Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood. 2008;111:3760-9 pubmed publisher
    ..Consistent with this result, overexpression of Bcl-xL led to decreased cellular proliferation. These models reveal an unexpected role for Bcl-xL in cell-cycle entry and the proliferation of tumor cells...
  77. Brady G, Farrell P. RUNX3-mediated repression of RUNX1 in B cells. J Cell Physiol. 2009;221:283-7 pubmed publisher
    ..Repression of RUNX1 by RUNX3 is required to allow the cell proliferation and this provides an experimental system to investigate the mechanism of the different activities of RUNX1 and RUNX3 in these cells...
  78. Costantini J, Cheung S, Hou S, Li H, Kung S, Johnston J, et al. TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia. Blood. 2009;114:4703-12 pubmed publisher
    ..These findings identify TAPP2 as a novel link between PI3K signaling and the cytoskeleton with potential relevance for leukemia progression...
  79. Panteli K, Bai M, Basioukas K, Vartholomatos G, Zioga K, Bourantas K. Skin and gingival lesions in a young woman with B-prolymphocytic leukemia (B-PLL). J Exp Clin Cancer Res. 2001;20:447-9 pubmed
    ..B-PLL has not been often associated with diffuse skin involvement or oral lesions. We present a 32 year-old woman in whom skin and gingival manifestations were the prominent clinical signs of disease relapse...
  80. Sorenson C, Sheibani N. Altered regulation of SHP-2 and PTP 1B tyrosine phosphatases in cystic kidneys from bcl-2 -/- mice. Am J Physiol Renal Physiol. 2002;282:F442-50 pubmed
    ..Thus renal cyst formation in the bcl-2 -/- mice may be the result of an inability of complete differentiation due to continued activation of growth processes, including activation of FAK and paxillin...
  81. Jung G, Eisenmann J, Thiebault S, Hénon P. Cell surface CD43 determination improves diagnostic precision in late B-cell diseases. Br J Haematol. 2003;120:496-9 pubmed
    ..6%. Inclusion of CD43 facilitates the diagnosis of B-lymphoproliferative disorders and improves their classification...
  82. Svahn J, Schiaffino M, Caruso U, Calvillo M, Minniti G, Dufour C. Severe lactic acidosis due to thiamine deficiency in a patient with B-cell leukemia/lymphoma on total parenteral nutrition during high-dose methotrexate therapy. J Pediatr Hematol Oncol. 2003;25:965-8 pubmed
    ..This case report indicates that lactic acidosis may be a front-line diagnosis in patients on TPN with lethargy and outlines the need for monitoring thiamine supply in TPN...
  83. Inoges S, Rodriguez Calvillo M, Lopez Diaz de Cerio A, Zabalegui N, Pérez Calvo J, Panizo C, et al. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica. 2003;88:1438-40 pubmed
  84. Gribben J. Indolent B-cell malignancies: immune recognition and antiself. Leuk Lymphoma. 2003;44 Suppl 3:S77-83 pubmed
    ..Candidate antigens include heteroclitic peptides from the immunoglobulin V region and newly identified antigens including the cytochrome P450 1B1. Clinical trials are ongoing in all these fields...
  85. Katz O, Barzilay E, Skaat A, Herman A, Mittelman M, Neumann D. Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. Acta Haematol. 2005;114:177-9 pubmed
  86. Hirshfeld E, Weiss L, Kasir J, Zeira M, Slavin S, Shapira M. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem . Bone Marrow Transplant. 2006;38:359-64 pubmed
    ..Administration of irradiated host antigen-presenting cells post transplantation may thus represent a potential approach for amplification of the alloreactive capacity of donor lymphocytes following stem cell transplantation...
  87. Kovar M, Tomala J, Chmelova H, Kovar L, Mrkvan T, Joskova R, et al. Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin. Cancer Res. 2008;68:9875-83 pubmed publisher
    ..Finally, we have also shown that elimination of some immunoescape mechanism (e.g., deletion of Treg) can significantly improve the therapeutic outcome of chemotherapy...
  88. Weston Bell N, Townsend M, Di Genova G, Forconi F, Sahota S. Defining origins of malignant B cells: a new circulating normal human IgM(+)D(+) B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population. Leukemia. 2009;23:2075-80 pubmed publisher
  89. Tabucchi A, Carlucci F, Rosi F, Guerranti R, Marinello E. Determination, activity and biological role of adenylosuccinate lyase in blood cells. Biomed Pharmacother. 2001;55:277-83 pubmed
    ..The activity was also analyzed in B-lymphocytes from patients with B-cell chronic lymphocytic leukemia. The biological role of adenylosuccinate lyase and its importance in regulating cellular levels of AMP is discussed...
  90. Westerheide S, Mayo M, Anest V, Hanson J, Baldwin A. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol. 2001;21:8428-36 pubmed
    ..Therefore, our results demonstrate that dysregulated expression of Bcl-3 potentiates the G(1) transition of the cell cycle by stimulating the transcription of the cyclin D1 gene in human breast epithelial cells...
  91. Koyama M, Oka T, Ouchida M, Nakatani Y, Nishiuchi R, Yoshino T, et al. Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest. 2003;83:1849-58 pubmed
    ..These data support the possibility that the SHP1 gene is one of the tumor suppressor genes...
  92. Cooper L, Al Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis. 2004;33:83-9 pubmed
    ..This review will demonstrate the redirected specificity of CD19-specific T cells and implementation of clinical trials using these cellular agents...